- Home
- JFR vs PHAR Comparison
JFR vs PHAR Comparison
Compare JFR & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JFR | PHAR |
|---|---|---|
| Founded | 2004 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | JFR | PHAR |
|---|---|---|
| Price | $7.44 | $15.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 742.4K | 20.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 11.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $27.92 |
| Revenue Next Year | N/A | $8.86 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.12 | $7.50 |
| 52 Week High | $8.59 | $21.34 |
Technical Indicators
Market Signals| Indicator | JFR | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 27.64 | 45.21 |
| Support Level | N/A | $15.72 |
| Resistance Level | $8.00 | $17.76 |
| Average True Range (ATR) | 0.06 | 0.63 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 26.14 | 38.84 |
Price Performance
Historical ComparisonAbout JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.